Bachelor of Clinical Medicine of Medical College, Master of Pharmaceutical Toxicology, Doctor, Doctoral Supervisor (Fudan, Medical and Engineering College, submitted);
She has been engaged in pharmacology teaching and scientific research in the Medical College for 11 years, and has twice won the scientific progress Award of Shandong Province;
Formerly served as a second level researcher and director of the National Shanghai New Drug Safety Evaluation Research Center (2006-2016), founded Shanghai Yinuosi Biotechnology Co., Ltd. as the founder, and served as the chairman (2010-2019);
New drug review experts, GLP inspection experts, members of the expert committee for special approval of anti COVID-19 drugs, and members of ICH working group of the State Drug Administration;
Also serving as the Vice Chairman of the Chinese Society of Toxicology; Honorary Director of the Drug Toxicology Special Committee of the Chinese Pharmacological Society; Director of the Toxicology Special Committee of the Shanghai Pharmacological Society; Member of the Scientific Committee of Shanghai Huashan Hospital; Review expert of the Shanghai Regional Ethics Committee;
As the project leader, I have undertaken more than 20 research tasks, including the National Major New Drug Development Special Project, the National Development and Reform Commission's "National Protein Biopharmaceuticals and Vaccine Development Special Project", the National Natural Science Foundation of China, and the Shanghai Municipal Science and Technology Commission's Biomedical Project, and established 51 new methods for drug toxicology research, partially filling the domestic gap; Published over 150 articles; Published 7 monographs and obtained 7 authorized invention patents;
We have provided over 7000 toxicological evaluation studies for over 2500 new drugs developed by over 500 domestic and foreign research and development enterprises. Among them, 24 first class new drugs have been approved for marketing, and more than 90 new drugs have successfully applied for clinical trials in countries such as the United States;
Participate in the writing of NMPA GLP inspection standards and the revision of the new version of GLP; I have written or participated in drafting 15 CDE safety guidelines;
11 years of experience in pharmacology and 27 years of experience in teaching and researching drug toxicology; 17 years of GLP/CRO management experience.